NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
SARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ('NAYA') (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ('IVC') fertility treatments, proudly supports the U.S. President's recent executive order aimed at reducing the cost of IVF and expanding access to fertility services. The order directs the Domestic Policy Council to develop policy recommendations within 90 days to protect IVF access and significantly lower out-of-pocket expenses and health plan costs for families dealing with infertility.
For many individuals and couples struggling with infertility, the high cost of IVF often makes treatment financially out of reach. The lack of comprehensive insurance coverage for fertility services in most states further compounds this challenge, forcing many patients to take on significant debt or forego treatment altogether.
'Infertility is a challenging medical condition, and no one should have to choose between financial stability and starting a family,' said Steve Shum, CEO of NAYA Biosciences. 'President Trump's executive order is a critical step in the right direction, and we stand ready to support efforts that make fertility treatments more accessible and affordable for all. In addition to our existing fertility clinic operations, we also believe our FDA-cleared INVOcell device and the IVC treatment process is uniquely positioned to offer an efficient, effective, and more affordable treatment solution, which is aligned with the administration's efforts to reduce costs.'
Currently, fewer than 20 states mandate some level of fertility coverage, leaving millions without insurance assistance. By addressing cost concerns, the administration's action has the potential to bring hope to those who have faced heartbreaking obstacles on their journey to parenthood.
'As a trusted partner in fertility care with centers in Wisconsin, Alabama, and Georgia, NAYA remains committed to providing high-quality, patient-centered treatment and advocating for policies that support individuals and families seeking to conceive. We look forward to working alongside policymakers, medical professionals, and advocacy groups to ensure that every hopeful parent has the opportunity to experience the joy of building a family,' Shum concluded.
About NAYA Women's HealthNAYA Women's Health is currently focused within the fertility marketplace. Our commercial strategy includes operating fertility-focused clinics providing treatment to patients via INVO Centers, LLC, our wholly owned subsidiary. We currently have two operational INVO Centers in the United States along with a conventional IVF clinic.
Naya Women's Health also includes the INVOcell medical device. The INVOcell is the first in vivo Intravaginal Culture ('IVC') system granted FDA clearance in the United States. We believe this novel device and procedure provides a more natural, safe, effective and economical fertility treatment for patients. Unlike conventional infertility treatments such as IVF where the eggs and sperm develop into embryos in a laboratory incubator, the INVOcell utilizes the women's vagina as an incubator to support a more natural fertilization and embryo development environment, and infertility treatment. We currently sell and distribute INVOcell into existing independently owned and operated fertility clinics as well as within our own INVO Center clinics.
About NAYA BiosciencesNAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health. Our proven hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics.
NAYA's expanding portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase 1/2a monotherapy trial in 2025, NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, NY-500, a PD-1 x VEGF bifunctional antibody for the treatment of HCC and other solid tumors, and NY-600 a PSMA x NKp46 bifunctional antibody for the treatment of metastatic Castration Resistant Prostate Cancer (mCRPC).
Safe Harbor StatementThis release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
NAYA Investor & Media ContactAnna Baran-DjokovicSVP, Investor Relations+1-305-615-9162anna@nayabiosciences.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
25 minutes ago
- UPI
FDA approves use of animal drugs to treat New World Screwworm
The Food and Drug Administration is seeking to prevent possible infestations of the New World Screwworm by authorizing the use of animal drugs. File Photo by Juan Manuel Blanco/EPA-EFE Aug. 20 (UPI) -- The Food and Drug Administration has authorized emergency use of animal drugs to treat and prevent infestations of the New World Screwworm, which poses an emerging threat to U.S. livestock and food security. The parasite infests warm-blooded animals and in rare cases humans, causing tissue damage and occasionally death. Though eradicated in both North and Central America a decades ago, the screwworm has progressed north since 2022 and is nearing the U.S. southern border. The U.S. Department of Health and Human Services said it issued a declaration on Tuesday allowing the FDA to issue emergency use authorizations for animal drugs to prevent infestations. "Today, we are taking decisive action to safeguard the nation's food supply from this emerging threat," HHS Secretary Robert F. Kennedy Jr. said in a statement. "This authorization equips FDA to act quickly, limit the spread of New World Screwworm and protect America's livestock." Endemic to Cuba, Haiti, Dominican Republic and the countries of South America, the New World Screwworm strikingly resembles a fly, but when in its larval stage it burrows into the flies of a living animals, such as livestock, the U.S. Department of Agriculture said. The United States has worked with Panama for decades to prevent the parasite's northward expansion, according to the USDA, which resulted in the eradication of the insect from the United States in 1966. There are no FDA-approved drugs for NWS, but through an Emergency Use Authorization, the FDA can permit the use of certain animal drug products that have been approved for other purposes or are available in other countries. "This emergency use authorization is another tool we can use in the fight against New World Screwworm," Agriculture Secretary Brooke Rollins said. "Our cattle ranchers and livestock producers are relying on the Trump administration to defend their livelihoods. Stopping this pest is a national security priority and we are linking arms across President [Donald] Trump's Cabinet to defend our borders and push back this threat."
USA Today
an hour ago
- USA Today
Democrats try to force nuns to pay for abortions. Sounds authoritarian to me.
Blue states like California and Pennsylvania refuse to leave the Little Sisters of the Poor alone – and couldn't care less about their religious beliefs. The Little Sisters of the Poor are back in the news. In case you've forgotten who they are and why they matter, let's briefly review what they're all about. According to the group's website, the Little Sisters' mission is to ensure that "the elderly and dying are cared for with love and dignity until God calls them home.' The Little Sisters work in 31 countries and began work in America in 1868. Today, the nuns operate about 20 homes in the United States. It's a lovely mission and one that they should be allowed to do in peace, free from interference from the government. No such luck, however. Blue states like California and Pennsylvania refuse to leave the Little Sisters alone and couldn't care less about their religious beliefs. Since the Obama administration's Affordable Care Act birth control mandate that required employers to provide contraceptives and abortion-inducing drugs in their health insurance plans, the Little Sisters have been locked in a legal battle for the past 14 years. Despite clear wins for the nuns and religious liberty at the U.S. Supreme Court in 2016 and 2020, Democrats continue to persecute the Little Sisters. Will they ever stop? Will the Little Sisters have to make a third trip to the Supreme Court? That's 'absurd.' A federal district court in Philadelphia has revived the vindictive fight, siding with Pennsylvania and New Jersey against a 2017 Trump administration religious conscience rule, which offered the nuns and other religious groups protection from the mandate. Now, these states want the Little Sisters to offer contraception and abortion drugs or face millions of dollars in fines. 'The district court blessed an out-of-control effort by Pennsylvania and New Jersey to attack the Little Sisters and religious liberty,' Mark Rienzi, president of the Becket Fund for Religious Liberty and lead attorney for the Little Sisters, said in a statement. 'It is absurd to think the Little Sisters might need yet another trip to the Supreme Court to end what has now been more than a dozen years of litigation over the same issue.' The Little Sisters will appeal this decision, but it truly is ridiculous that they must waste time fighting the government in this way, when all they want to do is serve people in need. And lest you think it's odd to be talking about nuns and contraception, the Little Sisters employ lay people who work as nurses, cooks and serve other roles in the group's homes for the elderly. The nuns don't want to be complicit in providing services that directly violate their deep belief in the sanctity of life, which guides their work. They shouldn't have to. There are other ways the government could provide contraceptives to these employees without pushing the nuns to do it. Progressives claim Trump is an authoritarian. They should look at themselves. For all the times we've been scolded about how Trump and his supporters are fascists and Nazis, progressives ought to take a hard look at themselves first. Democrats have decided their views on culture are the only ones that should matter, religious liberty be damned. Look at how liberal governments have gone after Catholic adoption agencies, Christian bakers, website designers and farmers and tried to force them to betray their faith just to participate in the public square. These are often yearslong court battles, much like the Little Sisters have undertaken. Thankfully, we have a strong First Amendment that protects our speech and religious freedom. And the Supreme Court keeps ruling on the side of protecting these essential liberties, which are promised in our Constitution. Supreme Court Justice Clarence Thomas, in writing the majority for the 2020 case, observed that the Little Sisters 'have had to fight for the ability to continue in their noble work without violating their sincerely held religious beliefs.' Five years later, the fight continues. It's time for Democrats to leave these nuns alone. Ingrid Jacques is a columnist at USA TODAY. Contact her at ijacques@ or on X: @Ingrid_Jacques
UPI
3 hours ago
- UPI
AAP recommends children receive COVID-19 vaccine
The American Academy of Pediatrics is recommending children as young as six months receive the COVID-19 vaccine, despite the Trump administration stating it is not necessary for healthy children. File Photo by John Angelillo/UPI | License Photo Aug. 20 (UPI) -- The United States' leading pediatrics association is recommending that children as young as six months old be inoculated against COVID-19, going against the Trump administration, which stopped recommending healthy children receive the vaccine. The American Academy of Pediatrics made the recommendation Tuesday in the publication of its childhood and adolescent immunization schedule for this year. The report specifically recommends that children be inoculated against COVID-19 between the ages of six and 23 months, stating that those in this age range are at the highest risk of suffering the worst effects of the disease. "Children younger than 2 years old are especially vulnerable to severe COVID-19 and should be prioritized for vaccination unless they have a known allergy to the vaccine or its ingredients," the AAP said in a release accompanying the report. The AAP recommendation goes against that of Health and Human Services Secretary Robert F. Kennedy Jr., who in late May said the U.S. Centers for Disease Control and Prevention was no longer recommending that "healthy children" be immunized against COVID-19. Kennedy, a known vaccine skeptic, cited "a lack of any clinical data" to support booster COVID-19 shots for children. That move prompted AAP and other leading medical groups to sue Kennedy in July for making "unilateral, unscientific changes" to federal vaccine policy, calling it an "assault on science public health and evidence-based medicine." "This administration is an existential threat to vaccination in America, and those in charge are only just getting started," Richard Hughes IV, partner at Epstein Becker Green and lead counsel in the case, said in a statement. "If left unchecked, Secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation's children." Kennedy in June also fired all members of the CDC's Advisory Committee on Immunization Practices and replaced them with his own appointees, including three who have spoken out against the COVID-19 vaccine, two of whom have served as witnesses in lawsuits against vaccine makers and one who served on the board of the nation's oldest anti-vaccine group.
